Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Review article: Oral, modified-release mesalazine formulations--proprietary versus generic.

A Forbes1, A Cartwright, S Marchant

  • 1St Mark's Academic Institute, St Mark's Hospital, Northwick Park, Harrow, UK. alastair.forbes@ic.ac.uk

Alimentary Pharmacology & Therapeutics
|May 21, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Managing Blood Pressure in Dialysis Patients: A Summary of UK Clinical Practice Guideline.

Kidney international reports·2026
Same author

Balancing Efficiency and Accuracy in Hepatitis C Rapid Antibody Testing: Insights From a Cluster Randomised Crossover Trial.

Journal of viral hepatitis·2025
Same author

The performance of small sample correction methods for controlling type I error when analyzing parallel cluster randomized trials: a systematic review of simulation studies.

Journal of clinical epidemiology·2025
Same author

TIAMAT- towards an interdisciplinary automated malnutrition screening tool.

Clinical nutrition ESPEN·2025
Same author

Standardising and simplifying the Global Leadership Initiative on Malnutrition (GLIM) for its more general application.

Clinical nutrition ESPEN·2024
Same author

A vanguard randomised feasibility trial comparing three regimens of peri-operative oxygen therapy on recovery after major surgery.

Anaesthesia·2023

Generic mesalazine products for inflammatory bowel disease require rigorous assessment. New regulatory standards are needed to ensure therapeutic equivalence for topical drug delivery, benefiting patients and physicians.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Drug Development

Background:

  • Mesalazine is a key treatment for inflammatory bowel disease (IBD).
  • Many oral, modified-release mesalazine products are nearing patent expiration, leading to generic development.
  • Current formulations are designed for topical action at the inflammation site, necessitating specific release profiles.

Purpose of the Study:

  • To evaluate the adequacy of standard regulatory processes for generic, topically acting, oral, modified-release mesalazine products.
  • To propose a more rigorous assessment framework for ensuring therapeutic equivalence of new mesalazine formulations.
  • To provide confidence for physicians and patients regarding the interchangeability and efficacy of generic mesalazine.

Main Methods:

Related Experiment Videos

  • Analysis of current regulatory assessment practices for modified-release drug products.
  • Review of the topical mechanism of action for mesalazine in IBD.
  • Proposal for a combined assessment approach including dissolution, bioequivalence, and clinical trials.

    • Main Results:

    • Standard systemic bioequivalence testing is insufficient for topically acting, oral, modified-release mesalazine.
    • Current guidelines recommend against interchangeability of oral, delayed-release mesalazine formulations.
    • A need exists for a more robust regulatory evaluation to ensure therapeutic equivalence.

    Conclusions:

    • Regulatory bodies should mandate a combination of dissolution testing, bioequivalence studies, and comparative clinical trials for new oral mesalazine products.
    • This comprehensive assessment is crucial for therapeutic equivalence and patient safety.
    • Enhanced regulatory rigor will ensure confidence in the use of generic modified-release mesalazine products for IBD management.